Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer ’s Disease to Stop for Lack of Efficacy

Dateline City: KENILWORTH, N.J. APECS Study in People with Prodromal Alzheimer ’s Disease to ContinueKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with mild-to-moderate Alzheimer ’s disease (AD).Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558Ian McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE @Merckread more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news